Cross-protective immunity against o‘nyong-nyong virus afforded by a novel recombinant chikungunya vaccine

Emerging mosquito-borne alphavirus infections caused by chikungunya virus (CHIKV) or o‘nyong-nyong virus (ONNV) are responsible for sporadic and sometimes explosive urban outbreaks. Currently, there is no licensed vaccine against either virus. We have developed a highly attenuated recombinant CHIKV candidate vaccine (CHIKV/IRES) that in preclinical studies was demonstrated to be safe, immunogenic and efficacious. In this study we investigated the potential of this vaccine to induce cross-protective immunity against the antigenically related ONNV. Our studies demonstrated that a single dose of CHIKV/IRES elicited a strong cross-neutralizing antibody response and conferred protection against ONNV challenge in the A129 mouse model. Moreover, CHIKV/IRES immune A129 dams transferred antibodies to their offspring that were protective, and passively transferred anti-CHIKV/IRES immune serum protected AG129 mice, independently of a functional IFN response. These findings highlight the potential of the CHIKV/IRES vaccine to protect humans against not only CHIKV but also against ONNV-induced disease.

► The CHIKV/IRES vaccine elicits cross-neutralizing antibody responses against ONNV.
► CHIKV/IRES immune animals are protected against ONNV challenge.
► Protection is mediated by antibodies as evident by passive transfer studies.
► CHIKV/IRES immune dams transfer protective anti-ONNV antibodies to their off springs.